[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL3365373T3 - Molekuły wiążące, które hamują wzrost nowotworu - Google Patents

Molekuły wiążące, które hamują wzrost nowotworu

Info

Publication number
PL3365373T3
PL3365373T3 PL16794080T PL16794080T PL3365373T3 PL 3365373 T3 PL3365373 T3 PL 3365373T3 PL 16794080 T PL16794080 T PL 16794080T PL 16794080 T PL16794080 T PL 16794080T PL 3365373 T3 PL3365373 T3 PL 3365373T3
Authority
PL
Poland
Prior art keywords
binding molecules
cancer growth
inhibit cancer
inhibit
growth
Prior art date
Application number
PL16794080T
Other languages
English (en)
Inventor
Mark Throsby
Ton Logtenberg
Johannes Carolus Clevers
Robert Gerhardus Jacob VRIES
Eduard BATLLE
Bram HERPERS
Original Assignee
Merus N.V.
Koninklijke Nederlandse Akademie Van Wetenschappen
Ocello B.V.
Fundació Institut De Recerca Biomèdica (Irb Barcelona)
Institució Catalana De Recerca I Estudis Avançats
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus N.V., Koninklijke Nederlandse Akademie Van Wetenschappen, Ocello B.V., Fundació Institut De Recerca Biomèdica (Irb Barcelona), Institució Catalana De Recerca I Estudis Avançats filed Critical Merus N.V.
Publication of PL3365373T3 publication Critical patent/PL3365373T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046Stomach, Intestines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL16794080T 2015-10-23 2016-10-21 Molekuły wiążące, które hamują wzrost nowotworu PL3365373T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15191343 2015-10-23
EP16168647 2016-05-06
PCT/NL2016/050726 WO2017069628A2 (en) 2015-10-23 2016-10-21 Binding molecules that inhibit cancer growth
EP16794080.8A EP3365373B1 (en) 2015-10-23 2016-10-21 Binding molecules that inhibit cancer growth

Publications (1)

Publication Number Publication Date
PL3365373T3 true PL3365373T3 (pl) 2021-08-23

Family

ID=57190021

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16794080T PL3365373T3 (pl) 2015-10-23 2016-10-21 Molekuły wiążące, które hamują wzrost nowotworu

Country Status (27)

Country Link
US (2) US11939394B2 (pl)
EP (2) EP3912998A3 (pl)
JP (3) JP7296728B2 (pl)
KR (1) KR20180100305A (pl)
CN (2) CN115925944A (pl)
AU (2) AU2016340764B2 (pl)
BR (1) BR112018008068A2 (pl)
CA (1) CA3002957A1 (pl)
CY (1) CY1124108T1 (pl)
DK (1) DK3365373T3 (pl)
EA (1) EA201890866A1 (pl)
ES (1) ES2865482T3 (pl)
HK (1) HK1253914A1 (pl)
HR (1) HRP20210483T1 (pl)
HU (1) HUE055222T2 (pl)
LT (1) LT3365373T (pl)
MA (2) MA45517B1 (pl)
MD (1) MD3365373T2 (pl)
MX (2) MX2018004988A (pl)
NZ (1) NZ742290A (pl)
PL (1) PL3365373T3 (pl)
RS (1) RS61800B1 (pl)
SG (1) SG11201803359VA (pl)
SI (1) SI3365373T1 (pl)
SM (1) SMT202100230T1 (pl)
WO (1) WO2017069628A2 (pl)
ZA (1) ZA201802758B (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3110846B1 (en) 2014-02-28 2020-08-19 Merus N.V. Antibodies that bind egfr and erbb3
CN106536556B (zh) * 2014-04-04 2020-02-07 生态学有限公司 结合lgr5的人源化抗体
CA3002957A1 (en) 2015-10-23 2017-04-27 Koninklijke Nederlandse Akademie Van Wetenschappen Binding molecules that inhibit cancer growth
JP2019509322A (ja) 2016-03-22 2019-04-04 バイオノミクス リミテッド 抗lgr5モノクローナル抗体の投与
JP7617603B2 (ja) 2017-01-11 2025-01-20 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー R-スポンジン(rspo)サロゲート分子
AU2018211985A1 (en) * 2017-01-26 2019-07-18 Surrozen Operating, Inc. Tissue-specific Wnt signal enhancing molecules and uses thereof
IL269656B2 (en) 2017-03-31 2024-06-01 Merus Nv Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene
CA3063849A1 (en) 2017-05-17 2018-11-22 Merus N.V. Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
AU2018297061B2 (en) * 2017-07-06 2021-05-06 Merus N.V. Antibodies that modulate a biological activity expressed by a cell
EP3649155A1 (en) * 2017-07-06 2020-05-13 Merus N.V. Bispecific anti pd1-anti tim3 antibodies
SG11202001050PA (en) 2017-08-09 2020-03-30 Merus Nv Antibodies that bind egfr and cmet
CN111936514A (zh) * 2018-03-30 2020-11-13 美勒斯公司 多价抗体
CA3104868A1 (en) * 2018-07-09 2020-01-16 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
AU2019416324A1 (en) * 2018-12-27 2021-07-22 H. Lee Moffitt Cancer Center And Research Institute Inc. Bispecific antibody for membrane clearance of target receptors
CN114249818A (zh) 2018-12-31 2022-03-29 美勒斯公司 截短的多价多元体
JP7443376B2 (ja) * 2018-12-31 2024-03-05 メルス ナムローゼ フェンノートシャップ 混合結合ドメイン
CN114426578A (zh) * 2019-02-14 2022-05-03 美勒斯公司 结合egfr、her2及her3的结合部分的组合
BR112021016094A2 (pt) * 2019-02-14 2021-10-26 Merus N.V. Combinações de porções de ligação que se ligam ao egfr, her2 e her3
EP3931224A4 (en) 2019-02-26 2023-03-01 Janssen Biotech, Inc. COMBINATION TREATMENTS AND PATIENT STRATIFICATION WITH ANTI-EGFR/C-MET BISPECIFIC ANTIBODIES
AU2020251578A1 (en) * 2019-04-04 2021-10-28 Ono Pharmaceutical Co., Ltd. Bispecific antibody
JOP20210304A1 (ar) 2019-05-14 2023-01-30 Janssen Biotech Inc علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
CA3151641A1 (en) 2019-08-19 2021-02-25 Merus N.V. Treatment of cancer with a combination of an antibody that binds lgr5 and egfr and a topoisomerase i inhibitor
CA3159745A1 (en) * 2019-11-01 2021-05-06 The Regents Of The University Of California Degradation of surface proteins using bispecific binding agent
WO2021176034A1 (en) * 2020-03-05 2021-09-10 Umc Utrecht Holding B.V. Membrane ubiquitin ligases to target protein degradation
BR112022021345A2 (pt) 2020-04-24 2022-12-27 Merus Nv Tratamento de cânceres com um anticorpo que se liga a lgr5 e egfr
EP4168442A1 (en) * 2020-06-18 2023-04-26 UMC Utrecht Holding B.V. Screening method for effective target - e3 ligase combinations
CN113862326B (zh) * 2020-09-08 2024-07-05 复旦大学 KREMEN1和/或ASGR1作为药物靶点在治疗SARS-CoV-2感染中的应用
KR20230120125A (ko) 2020-12-15 2023-08-16 메뤼스 엔.페. Lgr5 및 egfr에 결합하는 항체를 사용하는 암의 치료
EP4262867A1 (en) 2020-12-18 2023-10-25 Merus N.V. Antibody composition
CN114853889B (zh) * 2021-02-03 2024-03-01 中国科学院动物研究所 针对人gpr48的单克隆抗体及其应用
CN113307882B (zh) * 2021-05-12 2022-12-20 东北大学 靶向治疗Rspo过度激活导致的结直肠癌的融合蛋白SZ1及其偶联纳米药物
EP4413037A1 (en) 2021-10-06 2024-08-14 Merus N.V. Treatment of immune checkpoint inhibitor-treated cancers with high egfr expression using an antibody that binds at least egfr
WO2024136658A1 (en) 2022-12-23 2024-06-27 Merus N.V. Combination treatment of cancers using an antibody that binds at least egfr and an immune checkpoint inhibitor
TW202432606A (zh) 2022-12-28 2024-08-16 荷蘭商美勒斯公司 使用結合egfr的抗體及細胞毒性藥物的組合之癌症治療
CN116082510B (zh) * 2023-03-07 2023-12-05 四川尚锐生物医药有限公司 一种单克隆抗体或其抗原结合片段及其抗肿瘤的用途

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
NZ226694A (en) 1987-10-28 1994-04-27 Oncogen Human immunoglobulin produced by recombinant dna techniques
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
CA2111858A1 (en) 1991-07-15 1993-02-04 James S. Crowe Production of antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE29706518U1 (de) 1997-04-11 1997-05-22 E. Missel GmbH & Co., 70374 Stuttgart Trägersystem für Bade-, Dusch- oder Whirlwannen
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
ES2378272T3 (es) 1999-04-15 2012-04-10 Crucell Holland B.V. Producción de proteína recombinante en una célula humana
DE29915950U1 (de) 1999-09-10 1999-12-30 CMW Automation GmbH, 65594 Runkel Vorrichtung zum Elektrolytbefüllen der Zellen eines Akkumulators
US20070111201A1 (en) 2001-04-30 2007-05-17 Benjamin Doranz Reverse transfection of cell arrays for structural and functional analyses of proteins
CA2450020C (en) 2001-07-04 2013-08-13 Chromagenics B.V. Dna sequences comprising gene transcription regulatory qualities and methods for detecting and using dna sequences
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US20050130224A1 (en) 2002-05-31 2005-06-16 Celestar Lexico- Sciences, Inc. Interaction predicting device
AU2003250074B2 (en) 2002-07-18 2010-09-09 Merus N.V. Recombinant production of mixtures of antibodies
CA2512647C (en) 2003-01-07 2013-10-08 Symphogen A/S Method for manufacturing recombinant polyclonal proteins
WO2005000894A2 (en) 2003-06-25 2005-01-06 Crucell Holland B.V. Binding molecules for the treatment of myeloid cell malignancies
AU2005250499B2 (en) 2004-06-03 2011-12-08 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2008531557A (ja) 2005-02-23 2008-08-14 メリマック ファーマシューティカルズ インコーポレーティッド 生物活性を調節するための二重特異性結合剤
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
CA2646965C (en) 2006-03-24 2016-06-21 Jonathan H. Davis Engineered heterodimeric protein domains
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
US10118970B2 (en) 2006-08-30 2018-11-06 Genentech, Inc. Multispecific antibodies
US8290739B2 (en) 2006-10-20 2012-10-16 Amfit, Inc. Method for determining relative mobility of regions of an object
US8580263B2 (en) 2006-11-21 2013-11-12 The Regents Of The University Of California Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
US7846440B2 (en) 2007-02-16 2010-12-07 Merrimack Pharmaceuticals, Inc. Antibodies against ErbB3 and uses thereof
ES2667863T3 (es) 2007-03-29 2018-05-14 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
AU2008234019B2 (en) 2007-04-03 2014-05-29 Amgen Research (Munich) Gmbh Cross-species-specific bispecific binders
US7705103B2 (en) 2007-06-22 2010-04-27 3M Innovative Properties Company Polydiorganosiloxane polyoxamide copolymers
ES2553169T5 (es) 2007-07-02 2023-11-30 Oncomed Pharm Inc Composiciones y métodos para el tratamiento y el diagnóstico del cáncer
EP2211903A4 (en) 2007-10-17 2011-07-06 Nuvelo Inc CLL-1 ANTIBODY
EP2235536A4 (en) 2007-12-20 2011-05-04 Lab Corp America Holdings HER-2-DIAGNOSTIC PROCEDURE
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
MX350962B (es) 2008-01-07 2017-09-27 Amgen Inc Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion.
AU2009211148B2 (en) 2008-02-05 2014-08-28 Zymeworks Inc. Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics
SI2147594T1 (sl) 2008-06-27 2014-02-28 Merus B.V. Protitelo proizvajajoči ne-humani sesalci
JP5719298B2 (ja) 2008-08-29 2015-05-13 シムフォゲン・アクティーゼルスカブSymphogen A/S 組換え抗上皮増殖因子受容体抗体組成物
WO2010059315A1 (en) 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
CN102460152B (zh) 2009-01-15 2014-11-26 美国控股实验室公司 通过测量Her-3确定患者反应的方法
EP2389392A1 (en) 2009-01-26 2011-11-30 Genmab A/S Methods for producing mixtures of antibodies
EP2408817B1 (en) 2009-03-20 2016-03-16 F.Hoffmann-La Roche Ag Bispecific anti-her antibodies
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CN102471378B (zh) 2009-06-26 2014-04-02 瑞泽恩制药公司 容易地分离的具有天然免疫球蛋白形式的双特异性抗体
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
SG178509A1 (en) 2009-08-21 2012-04-27 Merrimack Pharmaceuticals Inc Antibodies against the ectodomain of erbb3 and uses thereof
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2496598B1 (en) 2009-11-04 2017-08-02 Affibody AB Her3 binding polypeptides
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
SI2505654T2 (sl) 2010-02-08 2020-08-31 Regeneron Pharmaceuticals, Inc. Miš z navadno lahko verigo
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
RU2608640C2 (ru) 2010-08-16 2017-01-23 Новиммун С.А. Способы получения мультиспецифичных и мультивалентных антител
ME02637B (me) 2010-08-20 2017-06-20 Novartis Ag Antitela za receptor 3 faktora rasta epiderma (her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
JP2014511383A (ja) 2011-02-24 2014-05-15 メリマック ファーマシューティカルズ インコーポレーティッド 抗ErbB3剤を含む併用療法
AU2012229062A1 (en) 2011-03-15 2013-04-11 Merrimack Pharmaceuticals, Inc. Overcoming resistance to ErbB pathway inhibitors
JP2014511836A (ja) 2011-03-25 2014-05-19 グレンマーク ファーマシューティカルズ, エセ.アー. ヘテロ二量体免疫グロブリン
GB201106395D0 (en) * 2011-04-14 2011-06-01 Hubrecht Inst Compounds
WO2012156309A1 (en) 2011-05-13 2012-11-22 Millegen Antibodies against her3
CA2840461A1 (en) 2011-06-20 2012-12-27 Kyowa Hakko Kirin Co., Ltd. Anti-erbb3 antibody
BR112014000765A2 (pt) * 2011-07-15 2017-06-13 Oncomed Pharm Inc agentes de ligação a rspo e seus usos
US9567827B2 (en) 2013-07-15 2017-02-14 Downhole Technology, Llc Downhole tool and method of use
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
KR20140069331A (ko) 2011-09-30 2014-06-09 리제너론 파아마슈티컬스, 인크. 항-ErbB3 항체 및 이의 용도
BR112014012539B1 (pt) 2011-11-23 2022-12-20 Medimmune, Llc Anticorpo que se liga especificamente a her3, composição compreendendo o mesmo, e usos do anticorpo
BR112014013495A8 (pt) 2011-12-05 2017-06-13 Novartis Ag anticorpos para o receptor 3 do fator de crescimento epidérmico (her3) direcionados para o domínio iii e domíniuo iv de her3
EA202092280A3 (ru) 2011-12-05 2021-09-30 Новартис Аг Антитела к рецептору эпидермального фактора роста 3 (her3)
CN102448183A (zh) 2012-01-18 2012-05-09 大唐移动通信设备有限公司 一种Uu接口重配置方法及设备
US9702824B2 (en) 2012-03-09 2017-07-11 Promega Corporation pH sensors
KR20140148388A (ko) 2012-03-27 2014-12-31 제넨테크, 인크. Her3 억제제와 관련된 진단 및 치료
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
CN114163530A (zh) 2012-04-20 2022-03-11 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
TW201843172A (zh) 2012-06-25 2018-12-16 美商再生元醫藥公司 抗-egfr抗體及其用途
AU2013324527B9 (en) 2012-09-27 2018-07-26 Merus N.V. Bispecific IgG antibodies as T cell engagers
EP2906591A1 (en) 2012-10-15 2015-08-19 Universität Zürich Bispecific her2 ligands for cancer therapy
PL2922872T3 (pl) 2012-11-21 2019-03-29 Janssen Biotech, Inc. Bispecyficzne przeciwciała przeciwko egfr/c-met
WO2014121196A1 (en) 2013-02-04 2014-08-07 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a wnt pathway inhibitor
US20160319034A1 (en) * 2013-03-14 2016-11-03 Oncomed Pharmaceuticals, Inc. Met-binding agents and uses thereof
US20160041171A1 (en) 2013-04-05 2016-02-11 Laboratory Corporation Of America Holdings Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation
JP2016520586A (ja) 2013-05-08 2016-07-14 ザイムワークス,インコーポレイテッド 二重特異性her2およびher3抗原結合性構築物
US9879081B2 (en) 2013-06-25 2018-01-30 Samsung Electronics Co., Ltd. Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
US9551208B2 (en) 2013-08-26 2017-01-24 Halliburton Energy Services, Inc. Identifying uncertainty associated with a stimulated reservoir volume (SRV) calculation
US10519247B2 (en) 2013-11-01 2019-12-31 Board Of Regents,The University Of Texas System Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
EP3110846B1 (en) 2014-02-28 2020-08-19 Merus N.V. Antibodies that bind egfr and erbb3
ES2826774T3 (es) 2014-02-28 2021-05-19 Merus Nv Anticuerpo que se une a ERBB-2 y ERBB-3
LT3126388T (lt) * 2014-03-11 2019-08-26 Regeneron Pharmaceuticals, Inc. Antikūnai prieš egfrviii ir jų panaudojimo būdai
CN106536556B (zh) 2014-04-04 2020-02-07 生态学有限公司 结合lgr5的人源化抗体
MA41123A (fr) 2014-12-02 2017-10-10 Oncomed Pharm Inc Polythérapie pour le traitement du cancer
US10383945B2 (en) * 2015-02-18 2019-08-20 The United States of America as Represented by the Department of Verterans Affairs Methods for DNA-dependent targeting of a cell permeant antibody
LT3115376T (lt) 2015-07-10 2018-11-12 Merus N.V. Antikūnai, kurie jungiasi su žmogaus cd3
CA3002957A1 (en) 2015-10-23 2017-04-27 Koninklijke Nederlandse Akademie Van Wetenschappen Binding molecules that inhibit cancer growth
JP6946304B2 (ja) * 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子15(gdf−15)を使用して代謝障害を処置するまたは軽快させる方法
EP3600411A1 (en) 2017-03-31 2020-02-05 Merus N.V. Antibodies for the treatment of erbb-2/erbb-3 positive tumors
IL269656B2 (en) 2017-03-31 2024-06-01 Merus Nv Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene
CA3063849A1 (en) 2017-05-17 2018-11-22 Merus N.V. Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
SG11202001050PA (en) 2017-08-09 2020-03-30 Merus Nv Antibodies that bind egfr and cmet
SG11202106764YA (en) * 2018-12-27 2021-07-29 Gigagen Inc Anti-ctla-4 binding proteins and methods of use thereof

Also Published As

Publication number Publication date
EP3912998A2 (en) 2021-11-24
CY1124108T1 (el) 2022-05-27
RS61800B1 (sr) 2021-06-30
CA3002957A1 (en) 2017-04-27
BR112018008068A2 (pt) 2018-11-13
CN115925944A (zh) 2023-04-07
JP2024023445A (ja) 2024-02-21
LT3365373T (lt) 2021-05-25
HK1253914A1 (zh) 2019-07-05
KR20180100305A (ko) 2018-09-10
WO2017069628A2 (en) 2017-04-27
JP7296728B2 (ja) 2023-06-23
EP3912998A3 (en) 2022-02-23
MA54760A (fr) 2022-04-13
CN108602888B (zh) 2022-10-04
AU2023222928A1 (en) 2023-09-21
DK3365373T3 (da) 2021-04-06
US20240343824A1 (en) 2024-10-17
AU2016340764A1 (en) 2018-05-17
MX2022000302A (es) 2022-02-03
EP3365373A2 (en) 2018-08-29
AU2016340764B2 (en) 2023-06-01
MX2018004988A (es) 2018-11-09
US20180312604A1 (en) 2018-11-01
MA45517A (fr) 2018-08-29
SMT202100230T1 (it) 2021-07-12
MD3365373T2 (ro) 2021-08-31
EP3365373B1 (en) 2021-03-10
MA45517B1 (fr) 2021-04-30
SI3365373T1 (sl) 2021-08-31
CN108602888A (zh) 2018-09-28
US11939394B2 (en) 2024-03-26
SG11201803359VA (en) 2018-05-30
JP2019500405A (ja) 2019-01-10
ZA201802758B (en) 2020-08-26
WO2017069628A9 (en) 2017-10-26
NZ742290A (en) 2019-11-29
HRP20210483T1 (hr) 2021-07-09
EA201890866A1 (ru) 2018-09-28
HUE055222T2 (hu) 2021-11-29
JP2023008754A (ja) 2023-01-19
WO2017069628A3 (en) 2017-09-08
ES2865482T3 (es) 2021-10-15

Similar Documents

Publication Publication Date Title
HK1253914A1 (zh) 抑制癌症生長的結合分子
HK1251407A1 (zh) 治療癌症的方法
HK1252791A1 (zh) 具有經修飾的j鏈的結合分子
IL277261A (en) Low molecular weight compounds for cancer treatment
PL3377516T3 (pl) Kompozycja do leczenia nowotworu
GB201612520D0 (en) Binding molecules
SG11201705583XA (en) Cxcr4 binding molecules
HK1250944A1 (zh) 用於治療癌症的方法
GB201702091D0 (en) Specific binding molecules
DK3292140T3 (en) Immunterapeutikum mod cancer
HK1245120A1 (zh) 用於癌症的新治療
HK1250942A1 (zh) 用於治療癌症的方法
HK1250943A1 (zh) 用於治療癌症的方法
ZA201707024B (en) Cancer treatment composition
GB2546773B (en) Cancer
GB201522433D0 (en) Cancer treatment
GB201508480D0 (en) Cancer
IL258866A (en) Binding molecules that inhibit cancer growth
PT3365373T (pt) Moléculas de ligação que inibem o crescimento do cancro
GB201508729D0 (en) Binding molecules
GB201503668D0 (en) Liver cancer